Nachrichten zur Biogen Inc. Aktie

Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) – Contact Kessler Topaz Meltzer & Check, LLP

RADNOR, Pa., June 22, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP…

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines – BIIB

NEW YORK, June 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm

NEW YORK, June 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Alzheimer’s Disease Treatment Stocks: 3 Biggest NASDAQ Companies in 2024

Alzheimer’s disease treatment stocks are focused on Alzheimer’s disease, a degenerative brain disorder that results in declining memory and thinking…

Alzheimers Drug Stocks: Investing in Eli Lilly, Biogen, Roche

The race to develop effective Alzheimers treatments presents significant opportunities and inherent risks for healthcare investors.…

BIOGEN STOCK NOTICE: Lose Money on your Biogen Inc. (Nasdaq: BIIB) Investment? BFA Law Encourages You to Contact the Firm before July 22, 2024 Court Deadline

Investors that suffered losses in their Biogen Inc. investment are encouraged to contact BFA Law firm before the July 22,…

Biogen Aktie: Neue Alzheimer-Medikamente Wettstreit

Alzheimer-Markt sieht potenziellen Wandel Nachdem die amerikanische Gesundheitsbehörde FDA im letzten Jahr Leqembi zur Therapie der frühen Alzheimersymptome zugelassen hatte,…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

The Zacks Analyst Blog Highlights Biogen, Eli Lillys, Prothena and AC Immune (Revised)

Biogen, Eli Lillys, Prothena and AC Immune are included in this Analyst Blog.…

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines – BIIB

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…

Biogen Inc. (BIIB) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)

…

FDA advisors recommend Eli Lillys Alzheimers drug donanemab, paving way for approval

If approved, Eli Lillys donanemab would become the second Alzheimers drug of its kind currently on the U.S. market after…

BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.

Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.…

Biogen, Eisai get January 2025 FDA action date for monthly Leqembi

…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm

NEW YORK, June 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Biogen (BIIB) & Eisais Leqembi sBLA Gets FDA Acceptance

FDA accepts Biogens (BIIB) partner Eisais sBLA for a maintenance intravenous dosing version of Alzheimers drug Leqembi. The final FDA…

FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

TOKYO and CAMBRIDGE, Mass., June 09, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito,…

Unpacking Alphabet’s CFO Search

Welcome to CFO Briefing, a new Bloomberg newsletter devoted to corporate finance and what leaders need to know. I’m Nina Trentmann, a senior…

Biogen Aktie: Sammelklagefrist Nähert Sich

Biogen, ein globaler biopharmazeutischer Konzern, sieht sich schwerwiegenden Vorwürfen im Rahmen einer Sammelklage gegenüber, welche nun Investoren auf den bevorstehenden…

Biogen Aktie: Sammelklage trifft Pharmakonzern

Biogen Inc. steht im Fokus einer Sammelklage wegen mutmaßlicher Verstöße gegen die Wertpapiergesetze. Der Vorwurf wiegt schwer: Die Anschuldigungen richten…

BIOGEN CASE DEADLINE: Biogen Inc. (Nasdaq: BIIB) Investors are Reminded of Upcoming July 2024 Legal Deadline and Encouraged to Contact BFA Law

NEW YORK, June 08, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP announces the…

Biogen Aktie: Schockierende Anschuldigungen aufgetaucht

Biogen Inc., ein weltweit agierendes biopharmazeutisches Unternehmen, sieht sich schwerwiegenden Vorwürfen ausgesetzt, die umfassende investorische Prozesse nach sich ziehen könnten.…

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Shareholders

NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Biogen Inc. ("Biogen"…

Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join – Contact The Gross Law Firm

NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)

LOS ANGELES, June 06, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the…

Biogen Inc. (BIIB) Q1 2024 Earnings Call Transcript

…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Biotech Stock Roundup: GSKs Litigation Update, BIIBs Drug Approval & Other Updates

GSK and Biogen (BIIB) are in the spotlight following litigation updates and drug approval, respectively.…

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines – BIIB

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…

Biogen Aktie: Sammelklage und Innovationen

Biogen Inc. steht aktuell sowohl juristisch als auch innovationstechnisch stark im Licht der Öffentlichkeit. Das Unternehmen, bekannt für die Entwicklung…

Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel

CAMBRIDGE, Mass. and ATLANTA, June 03, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Delta Flight Products…

BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO, June 02, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or…

Biogen Aktie: Frist für Sammelklage Bekannt

Die globale Rechtsschmiede, bekannt für bedeutende Prozesserfolge im Bereich des Anlegerrechts, macht Investoren darauf aufmerksam, dass eine bedeutende Frist im…

BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm

NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…

BIIB (NASDAQ) FRAUD ALERT: Biogen Inc. Investors who Lost Money are Encouraged to Contact BFA Law about Upcoming Legal Deadline

NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP announces the…

BIIB Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Biogen Inc. Class Action

Robbins LLP is Investigating Allegations that Biogen Inc. (BIIB) Misled Investors Regarding its Financial Prospects…

Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody

Biogens (BIIB) Qalsody is the first therapy approved to treat a rare genetic form of ALS in Europe…

Biogen Aktie: Sammelklage und Überwachung

Nach Vorwürfen bezüglich irreführender Angaben und Compliance-Verstößen sieht sich Biogen Inc., ein global agierendes biopharmazeutisches Unternehmen, mit einer Sammelklage sowie…

EU approves Biogen treatment for genetic form of ALS

…

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the European Commission (EC) has…

Biogen Inc. (Nasdaq: BIIB) Investors Notice: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses.…

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm

The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm…

Verlustreicher Tag für Biogen-Aktionäre: Aktienkurs sinkt deutlich (195,4727 €)

Keinen Grund zur Freude haben Aktionäre von Biogen : Das Papier verliert deutlich an Wert. Das Wertpapier von Biogen gehört…

BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm

NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…

Biogen Aktie: Sammelklage wegen Irreführung

Biogen, ein weltweit agierendes biopharmazeutisches Unternehmen, steht aktuell im Brennpunkt einer Sammelklage. Die Klage richtet sich gegen erfolgte Aktienkäufe des…

BIIB INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO, May 25, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd…

Biogen Aktie: Klage und Umsatzrückgang

Biogen sieht sich mit einer Sammelklage konfrontiert, da Anleger in den USA Klage gegen das Unternehmen eingereicht haben. Die Beschwerde…

BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm

NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…

Stockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against Biogen Inc. (BIIB)

Robbins LLP is Investigating Allegations that Biogen Inc. (BIIB) Misled Investors Regarding its Financial Prospects…

BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.

BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against…